IP Library › Patent Application 15826909
Patent Application
App. No. 15/826,909

DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/826,909
Abstract

Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient.

Claims (19)

1 - 220 . (canceled)

221 . A method for treating a patient with mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof, the method comprising:

a) producing amplified labeled nucleic acid molecules that correspond to miR-202-3p, miR-483-5p, miR-31-5p, and miR-192-5p from a biological sample of a patient who has been determined to have pancreatic neoplastic cells

b) measuring the levels of expression of the amplified labeled nucleic acid molecules;

c) calculating a risk score based upon the measured levels of the amplified labeled nucleic acid molecules that identifies the sample as containing pancreatic cells that are characterized as mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof; and

d) treating the patient that has the biological sample that has been identified as having mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof with chemotherapy or radiation.

222 . The method of claim 221 , wherein the label is non-radioactive.

223 . A composition comprising amplified labeled nucleic acid molecules that correspond to miR-202-3p, miR-483-5p, miR-31-5p, and miR-192-5p or at least one of the following diff pair miRNAs: miR-10b-5p, miR-21-5p, miR-31-5p, miR-98, miR-125-3p, miR-130b-3p, miR-134, miR-135a-5p, miR-135b-5p, miR-192-5p, miR-194-5p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-202-3p, miR-203, miR-210, miR-224-5p, miR-323-3p, miR-337-5p, miR-345-5p, miR-363-3p, miR-379-5p, miR-382-5p, miR-429, miR-483-5p, miR-485-3p, miR-485-5p, miR-489, miR-708-5p, or miR-885-5p.

224 . The composition of claim 223 , wherein the label is non-radioactive.

225 . A method for treating a patient with mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof, the method comprising:

a) producing amplified labeled nucleic acid molecules from a biological sample from the patient that correspond to at least one of the following diff pair miRNAs: miR-10b-5p, miR-21-5p, miR-31-5p, miR-98, miR-125-3p, miR-130b-3p, miR-134, miR-135a-5p, miR-135b-5p, miR-192-5p, miR-194-5p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-202-3p, miR-203, miR-210, miR-224-5p, miR-323-3p, miR-337-5p, miR-345-5p, miR-363-3p, miR-379-5p, miR-382-5p, miR-429, miR-483-5p, miR-485-3p, miR-485-5p, miR-489, miR-708-5p, or miR-885-5p;

b) measuring the level of expression based upon the amplified labeled nucleic acid molecules of at least one of the following diff pair miRNAs: miR-10b-5p, miR-21-5p, miR-31-5p, miR-98, miR-125-3p, miR-130b-3p, miR-134, miR-135a-5p, miR-135b-5p, miR-192-5p, miR-194-5p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-202-3p, miR-203, miR-210, miR-224-5p, miR-323-3p, miR-337-5p, miR-345-5p, miR-363-3p, miR-379-5p, miR-382-5p, miR-429, miR-483-5p, miR-485-3p, miR-485-5p, miR-489, miR-708-5p, or miR-885-5p, wherein at least one of the miRNAs is a biomarker miRNA and one is a comparative miRNA;

c) determining at least one biomarker diff pair value based on the level of expression of the biomarker miRNA compared to the level of expression of the comparative miRNA;

d) determining whether the neoplastic pancreatic cells are mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof, based on the biomarker diff pair value(s), and

e) treating the patient that has a neoplastic pancreatic cells that have been identified as having mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN), or a subtype thereof with chemotherapy or radiation.

226 . The method of claim 225 , wherein the diff pair miRNAs comprises miR-130b-3p, miR-192-59, miR-202-3p, and miR-337-5p.

227 . The method of claim 225 , wherein the diff pair miRNAs comprises miR-10b-5p, miR-202-3p, miR-210, and miR-375.

228 . The method of claim 225 , wherein the diff pair miRNAs comprises miR-31-5p, miR-99a-5p, miR-375, and miR-483-5p.

229 . The method of claim 225 , wherein the diff pair miRNAs comprises miR-21-5p, miR-375, miR-485-3p, and miR-708-5p.